Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus

BACKGROUND: Dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG/DRV/c) is reasonable alternative option for patients with existing resistance and/or intolerance to nucleoside reverse transcriptase inhibitors (NRTIs). MATERIAL AND METHODS: All patients who switched to DTG/DRV/c amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang-Ah, Kim, Shin-Woo, Chang, Hyun-Ha, Jung, Hyejin, Kim, Yoonjung, Hwang, Soyoon, Kim, Sujeong, Park, Han-Ki, Lee, Jong-Myung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167504/
https://www.ncbi.nlm.nih.gov/pubmed/30270584
http://dx.doi.org/10.3947/ic.2018.50.3.252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167504/
https://www.ncbi.nlm.nih.gov/pubmed/30270584
http://dx.doi.org/10.3947/ic.2018.50.3.252

Ejemplares similares